These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16204260)

  • 1. Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001.
    Hartz I; Njølstad I; Eggen AE
    Eur Heart J; 2005 Dec; 26(24):2673-80. PubMed ID: 16204260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why do sales of lipid-lowering drugs vary between counties in Norway? Evidence from the OPPHED Health Study 2000-2001.
    Hartz I; Njølstad I; Furu K; Skurtveit S; Elise Eggen A
    Scand J Prim Health Care; 2006 Jun; 24(2):115-21. PubMed ID: 16690561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment].
    Buitrago F; Cañón-Barroso L; Díaz-Herrera N; Cruces-Muro E; Escobar-Fernández M; Serrano-Arias JM
    Rev Esp Cardiol; 2007 Feb; 60(2):139-47. PubMed ID: 17338879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are at-risk New Zealand women receiving recommended cardiovascular preventive therapy?
    Bupha-Intr O; Rose SB; Lawton BA; Elley CR; Dowell AC
    N Z Med J; 2010 Feb; 123(1309):26-36. PubMed ID: 20186240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Siblings of myocardial infarction patients are overlooked in primary prevention of cardiovascular disease.
    Hengstenberg C; Holmer SR; Mayer B; Engel S; Schneider A; Löwel H; Riegger GA; Schunkert H
    Eur Heart J; 2001 Jun; 22(11):926-33. PubMed ID: 11428816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Model for estimation of cardiovascular risk in Norway].
    Selmer R; Lindman AS; Tverdal A; Pedersen JI; Njølstad I; Veierød MB
    Tidsskr Nor Laegeforen; 2008 Jan; 128(3):286-90. PubMed ID: 18264151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention of coronary heart disease in the elderly.
    Dornbrook-Lavender KA; Pieper JA; Roth MT
    Ann Pharmacother; 2003 Nov; 37(11):1654-63. PubMed ID: 14565805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden.
    Journath G; Hellénius ML; Petersson U; Theobald H; Nilsson PM;
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):258-62. PubMed ID: 18525379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Great discrepancies between European, Dutch and Belgian criteria for the use of statins in the prevention of primary cardiovascular disease in family practice].
    Van Diest E; Stoffelen E; Wydooghe L; Van Duppen D; Seuntjens L; Van der Stuyft P
    Ned Tijdschr Geneeskd; 2001 Feb; 145(8):361-6. PubMed ID: 11257816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk.
    Rafter N; Connor J; Hall J; Jackson R; Martin I; Parag V; Vander Hoorn S; Rodgers A
    N Z Med J; 2005 Oct; 118(1223):U1676. PubMed ID: 16224500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators.
    Oriol-Zerbe C; Abholz HH
    Eur J Gen Pract; 2007; 13(1):27-34. PubMed ID: 17366291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guidelines for pharmacological primary prevention of cardiovascular diseases--who should be treated?].
    Fretheim A; Bjørndal A; Oxman AD; Dyrdal A; Golding M; Ose L; Reikvam A; Teisberg P
    Tidsskr Nor Laegeforen; 2002 Sep; 122(23):2277-81. PubMed ID: 12448268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consequences of using different methods to assess cardiovascular risk in primary care.
    Fornasini M; Brotons C; Sellarès J; Martinez M; Galán ML; Sáenz I; da Pena JM
    Fam Pract; 2006 Feb; 23(1):28-33. PubMed ID: 16243952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular risk reduction: impact of an international project].
    Colle B; Brusaferro S;
    Ann Ig; 2008; 20(3 Suppl 1):43-8. PubMed ID: 18773604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.
    Metcalf PA; Wells S; Scragg RK; Jackson R
    N Z Med J; 2008 Sep; 121(1281):49-57. PubMed ID: 18797484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany.
    Raum E; Lietzau S; Stegmaier C; Brenner H; Rothenbacher D
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):485-94. PubMed ID: 18383562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.